A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Phase 1

Not yet recruiting

• Conditions: Herpes Zoster (HZ)
• Interventions: Biological: Recombinant herpes zoster vaccine with low-dose adjuvant; Biological: Recombinant herpes zoster vaccine with high-dose adjuvant; Biological: Low-dose adjuvant; Biological: High-dose adjuvant; Biological: Shingrix (GSK); Biological: Normal Saline

• Registration Number: NCT06932523
• Lead Sponsor: Shanghai Institute Of Biological Products

Brief Summary

The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).

Detailed Description

There are two parts of the study.

Substudy A:

This substudy is the Phase I portion of the study. In this substudy, participants will receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or adjuvant controls or normal saline intramuscularly. Participants will be divided into 2 age groups: 40-49 years old and ≥ 50 years old. Participants will receive vaccinations on days 0 and 60. Participants will complete a 12-month safety follow-up after two doses of vaccination, and they will take part in this study for about 14 months.

Substudy B:

This substudy is the Phase Ⅱ portion of the study. In this part of the study, participants will also receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or normal saline intramuscularly. Participants will be divided into 3 age groups: 40-49 years old, 50-69 years old and ≥ 70 years old. Participants will receive vaccinations on days 0 and 60. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants will be involved in this study for up to 2 years.

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-10
• Study First Submitted QC: 2025-04-10
• Last Update Submitted: 2025-04-10
• Study First Posted: 2025-04-17
• Last Update Posted: 2025-04-17
• Study Start: 2025-06-01
• Primary Completion: 2026-06-30
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 645

Inclusion Criteria

• Age ≥ 40 years old on the day of enrollment, gender not limited.
• Can provide legal proof of identity.
• Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment.
• Be able to participate in all planned follow-up visits and comply with all trial procedures.
• On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature).
• Chronic disease patients need to be in a stable period of chronic disease.
• Female and male participants of childbearing age agreed to adopt strict and effective contraceptive measures from the start of the trial to 6 months after full exemption.

Exclusion Criteria

• Individuals with a history of herpes zoster in the past.
• Individuals with a history of vaccination against chickenpox or shingles.
• Individuals who have had close contact with patients with chickenpox or shingles in the past 2 years.
• Women of childbearing age who have a positive urine pregnancy test, are breastfeeding, pregnant, or plan to become pregnant within 6 months after the start of the test and the full exemption period.
• Individuals who are allergic to any component of the vaccine or have a history of other severe allergies.
• Use immunoglobulin and/or any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period.
• Have taken antipyretic, analgesic, or anti allergic drugs within 72 hours prior to receiving the experimental vaccine.
• Any experimental or unregistered product (drug, vaccine, biological product or device) other than the experimental vaccine has been used within one month prior to vaccination, or is planned to be used during the trial period.
• Administer non live vaccines within 7 days prior to administering the experimental vaccine or live vaccines within 14 days prior to administering the experimental vaccine.
• Suffering from a serious illness that prevents the completion of the entire experiment.
• Received immunosuppressive therapy or other immunomodulatory drugs, monoclonal antibodies, thymosin, interferon, etc. within 6 months prior to vaccination with the experimental vaccine, or planned to receive such treatment within 1 month after the first dose to full immunization, but local medication is allowed.
• Chemotherapy, radiotherapy, and organ and bone marrow transplantation related treatments for cancer or other diseases.
• Diseases or medical measures that lead to immune dysfunction
• Individuals currently suffering from serious infectious diseases such as active tuberculosis and active viral hepatitis.
• Moderate or severe acute illness/infection, or febrile illness within 72 hours prior to vaccination.
• Known to have a history of thrombocytopenia, any coagulation dysfunction, or being treated with anticoagulants.
• Suffering from serious cardiovascular disease, pulmonary edema, serious liver and kidney disease, and diabetes that cannot be controlled by drugs.
• Previous history of mental and neurological disorders or family history of mental illness.
• Currently suffering from various severe infectious, suppurative, and allergic skin diseases.
• Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit.
• (Phase I ) Abnormal blood routine, blood biochemistry, coagulation, and urine routine indicators before vaccination (excluding those judged by doctors to have no clinical significance).
• Any situation that the researcher believes may affect the evaluation of the experiment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SubStudy A (SSA): Group 1	Recombinant herpes zoster vaccine with low-dose adjuvant	Recombinant herpes zoster vaccine with low-dose adjuvant
SSA: Group 2	Recombinant herpes zoster vaccine with high-dose adjuvant	Recombinant herpes zoster vaccine with high-dose adjuvant
SSA:Control group 1	Low-dose adjuvant	Low-dose adjuvant
SSA:Control group 2	High-dose adjuvant	High-dose adjuvant
SSA: Positive control	Shingrix (GSK)	Shingrix (GSK)
SSA: Placebo group	Normal Saline	Normal saline
SubStudy B (SSB): Group 3	Recombinant herpes zoster vaccine with low-dose adjuvant	Recombinant herpes zoster vaccine with low-dose adjuvant
SSB: Group 4	Recombinant herpes zoster vaccine with high-dose adjuvant	Recombinant herpes zoster vaccine with high-dose adjuvant
SSB: Positive control	Shingrix (GSK)	Shingrix (GSK)
SSB: Placebo group	Normal Saline	Normal saline

Primary Outcome Measures

Name	Time	Method
Serious Adverse Events (SAE)	12 months after the last dose	That is serious adverse events, any serious adverse events that occurred to the participant during the study period.
Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies	30 days after the last dose of vaccination	GMC levels o of Anti-gE Antibodies in participants after receiving 2 doses of vaccine.
Geometric Mean Titer (GMT) of Anti-VZV Antibodies	30 days after the last dose of vaccination	GMT levels o of Anti-VZV Antibodies in participants after receiving 2 doses of vaccine.
Positive rate of Anti-gE Antibodies	30 days after the last dose of vaccination	The proportion of individuals in the study population who have achieved Anti-gE antibody positive after immunization.
Positive rate of Anti-VZV Antibodies	30 days after the last dose of vaccination	The proportion of individuals in the study population who have achieved Anti-VZV antibody positive after immunization.
Seroconversion rate of Anti-gE Antibodies	30 days after the last dose of vaccination	The proportion of individuals in the study population who have achieved Anti-gE antibody seroconversion after immunization.
Seroconversion rate of Anti-VZV Antibodies	30 days after the last dose of vaccination	The proportion of individuals in the study population who have achieved Anti-VZV antibody seroconversion after immunization.
Percentage of immediate Adverse Events (AEs)	30min after each dose of vaccination	The occurrence of any adverse events within 30 minutes after each dose of vaccination.
Percentage of solicited Adverse Events	14 days after each dose of vaccination	Adverse events defined by the protocol that occurred to the participant during 0-14 days after each dose of vaccination.
Percentage of unsolicited Adverse Events	28 or 30 days after each dose of vaccination	Other adverse events that occurred among participants within 0-28/30 days after each vaccination, in addition to the solicited adverse events.

Secondary Outcome Measures

Name	Time	Method
SSB： Cellular immune level	30 days, 6 months, 12months and 24 months after the last dose of vaccination	Levels of glycoprotein E (gE)-specific CD4+/CD8+ T cells expressing 2 or more markers of activation.
SSB：Humoral immunogenicity level	6 months, 12months and 24 months after the last dose of vaccination	Levels of GMC (Anti-gE antibody), GMT (Anti-VZV antibody), positive rate and seroconversion rate after receiving 2 doses of vaccine.